• Erlotinib and EGFR–CXCR4 Signaling: Heteromer Insight

  2026-10-09

  Erlotinib, also known as NSC 718781, offers a focused way to interpret EGFR kinase dependence within CXCR4–EGFR receptor complexes. This article examines what the 2026 Comez et al. study establishes, what remains unresolved, and how kinase inhibition can be connected cautiously to signaling and cancer-cell phenotypes.

• H-89 and Wnt–PKA Signaling in Bone Formation

  2026-10-09

  A source-grounded overview of how H-89 may inform research on PKA-linked Wnt signaling, O-GlcNAcylation, glycolysis, and osteogenesis. The discussion separates findings from the 2024 bone study from supplier claims and emphasizes pharmacological specificity, model limitations, and the absence of evidence that H-89 itself is a bone-building therapy.

• ARID1A-Linked Melanoma Resistance Networks

  2026-10-08

  The reference study uses integrative multi-omics and network analysis to examine early drug responses in BRAF-driven melanoma, comparing a sensitive model with an ARID1A-knockout resistant derivative. Its findings connect persistent MAPK and JNK signaling, altered PRKD1 and JUN activity, receptor-kinase changes, and immune-relevant remodeling into a systems-level model of resistance.

• LY2228820 and p38 MAPK Research Evidence

  2026-10-08

  LY2228820 is a research tool for studying p38α/β MAPK signaling, inflammation, stress responses, and cancer biology. The supplied commercial description reports biochemical and preclinical activity, while the cited 2025 airway-stent study evaluated a different combination of anlotinib and silver nanoparticles. This overview separates those evidence streams and defines their applicability limits.

• LDN-193189: BMP Signaling Evidence and Limits

  2026-10-07

  LDN-193189 is a research small molecule used to investigate BMP type I receptor signaling, particularly ALK2 and ALK3. The supplied evidence supports a cautious interpretation: supplier-reported pathway activity provides mechanistic rationale, while the cited mammary-cell study offers important context on TGF-β, Sca-1, plasticity, and Smad signaling but does not, in the supplied material, establish a compound-specific LDN-193189 result.

• CUDC-907 Product Overview

  2026-10-07

  CUDC-907 (SKU A4097) is described by APExBIO as a dual PI3K and HDAC inhibitor for cancer-signaling research. No matched paper evidence was supplied, so this overview is limited to documented product identity and conceptual scope.

• Pexmetinib (ARRY-614): Beyond Dual-Target Inhibition

  2026-10-06

  Pexmetinib (ARRY-614) offers a useful model for interpreting dual-target kinase inhibition across inflammatory and hematologic research. This article distinguishes its p38 MAPK/Tie2 profile from a newer phosphatase-centered concept involving p38α dephosphorylation, clarifying what the evidence supports and where extrapolation should stop.

• Sorafenib Beyond Kinase Potency: Reading Angiogenesis Data

  2026-10-06

  Sorafenib, also known as BAY-43-9006, is more than a multikinase inhibitor: it is a useful cancer biology research tool for separating tumor-cell signaling from vascular effects. This article interprets its antiangiogenic evidence, compares assay contexts, and examines what recent VEGFR-2 inhibitor research can—and cannot—establish.

• Netarsudil: From ROCK Inhibition to siRNA Codelivery

  2026-10-05

  Netarsudil (AR-13324) is more than a ROCK pathway probe: emerging evidence positions it as both a cytoskeletal modulator and an ionizable small-molecule component for siRNA codelivery. This article separates established biology from formulation-specific findings and clarifies the boundaries of translational interpretation.

• LY2228820 and the Next Era of p38 MAPK Research

  2026-10-05

  LY2228820 offers a focused way to interrogate p38α/β signaling, while new structural work suggests that kinase inhibitors may also influence phosphatase access to activation-loop phosphorylation sites. This thought-leadership perspective separates established product-reported findings from emerging hypotheses and outlines a translational framework for inflammation and oncology research.

• IPA-3 in Pak1 and GCRV Entry Research

  2026-10-04

  IPA-3 is commonly described as a non-ATP-competitive Pak1 inhibitor, but the supplied evidence shows that its value depends strongly on biological context. In a 2018 grass carp reovirus study, IPA-3 did not inhibit viral entry or infection in CIK cells, while pharmacological and imaging evidence supported a clathrin-, dynamin-, and endosome-acidification-dependent entry model.

• Betulinic Acid, ERK, and Cyclophosphamide Liver Injury

  2026-10-03

  A 2025 Environmental Toxicology study identifies betulinic acid as a protective intervention in cyclophosphamide-induced liver injury in mice, linking reduced oxidative stress with NRF2 activation, ERK-MAPK suppression, improved mitochondrial dynamics, and lower apoptotic signaling. Its PD98059 perturbation arm strengthens the proposed ERK–mitochondrial apoptosis mechanism, while the animal-only design limits direct translation to clinical hepatoprotection.

• Busulfan Workflows for Germ-Cell Tracing

  2026-10-02

  Busulfan is a DNA alkylating agent that can create controlled cellular stress, senescence, and germ-cell depletion models. When paired with dual-recombinase lineage tracing, it helps distinguish loss of pre-existing germ cells from evidence of true ovarian regeneration.

• 17-AAG (Tanespimycin) Cancer Workflow

  2026-10-01

  Build reproducible HSP90 inhibition experiments with 17-AAG, from fresh-solution preparation and dose-response design to client-protein degradation and apoptosis readouts. The workflow also shows how a recent norovirus study can sharpen assay logic without implying antiviral activity for Tanespimycin.

• Thiazovivin ROCK Inhibitor Workflow Guide

  2026-10-01

  Thiazovivin is a ROCK inhibitor used to support fibroblast reprogramming for induced pluripotent stem cell generation and to improve human embryonic stem cell survival after trypsinization. This dossier-based guide covers preparation, controls, storage, and troubleshooting for in vitro stem cell research; it does not establish clinical use, diagnostic performance, or universal dosing.

8512 records 1/568 page Next 12345 下5页 Last page